[en] Setting Early diagnosis of sickle cell disease decreases morbidity. However, cost-effective screening programmes are not yet available. Methods We explored the feasibility of systematic screening performed on dried blood harvested from five-day-old newborns. Results A total of 27,010 samples were collected in Belgian maternity units between June 2003 and February 2005, and the presence of haemoglobin (Hb) C or S in the eluted blood was examined by an enzyme-linked immunosorbent assay (ELISA) test performed with a monoclonal antibody detecting both mutated forms. As this antibody slightly cross-reacts with Hb A, better specificity is achieved if the test is performed not later than day 5. Among the 27,010 samples, 132 (0.49%) were positive. Molecular biology tests performed on dried blood from positive samples showed that 106 of these babies were heterozygotes for the Hb S mutation and three were heterozygotes for the Hb C mutation, while three newborns were SS homozygotes (0.011%). Seventeen samples (0.063%) were false-positives as we could not detect any mutation. Conclusions We have developed a new immunological approach in the field of haemoglobinopathy neonatal screening. This ELISA test is cheap (E0.2 /test or E1800/cletected SS homozygote) and could be centralized. Its cost-effectiveness in the whole Belgian population is comparable with that of screening for phenylketonuria or congenital adrenal hyperplasia. Further improvements should obviously be achieved in order to better discriminate heterozygotes and homozygotes, but the accessibility and the low cost of the test are relevant arguments for the screening extension in a wide range of countries, especially in Central Africa.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Boemer, François ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine
Guthrie R, Susu A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338
Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979;3:472-4
Cacciari E, Balsamo A, Piazzi S, et al. Neonatal screening for congenital adrenal hyperplasia. Lancet 1982;8:1069
Ehrlich RM, McKendry JB. Screening for congenital hypothyroidism in the newborn. Lancet 1973;19:1121
Carreiro-Lewandowski E. Newborn screening: an overview. Clin Lab Sci 2002;15:229-38
Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;364:6593-9
Consensus Development Panel, National Institutes of Health. Newborn screening for sickle cell disease and other hemoglobinopathies. J Am Med Assoc 1987;258:6205-9
Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 6988;86:749-55
Harris MS, Eckman JR. Georgia's experience with newborn screening: 6986 to 6985. Pediatrics 1989;83:858-60
Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services 1993; Clinical Practice Guideline No. 6. AHCRP Pub. No 93-0562
AAP Newborn Screening Taskforce. Serving the family from birth to the medical home: Newborn screening: a blueprint for the future. Pediatrics 2000;106:389-422
Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines: follow-up of children, diagnosis, management, and evaluation. J Pediatr 2000;137:S1-46
Eckman JR. Neonatal screening. In: Embury SH, Hebbell RP, Mohandas N, Steinburg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press, 1994;509-15
Papadea C, Eckman JR, Kuehner R, et al. Comparison of liquid cord blood and filter paper spots for newborn hemoglobin screening: laboratory and programmatic issues. Pediatrics 1994;93:427-32
Ou CN, Rognerud Cheryl. Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clin Chem 1993;39:820-4
Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-24
Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997;100:1193-8
Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996;97:1227-34
Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-6
Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81-6